Published on 12/02/2026 Lecture time : 3 minutes
Published on 12/02/2026 Lecture time : 3 minutes
In clinical trials sponsored by biotech and medtech companies, the success of a study often depends on a key factor that is sometimes underestimated: the selection of investigator sites.
A poor match can cost months—or even jeopardize an entire trial.
Site selection criteria, as defined in the monitoring plan, are discussed with shortlisted sites through various channels (questionnaires, calls, or on-site visits). These exchanges help assess interest, experience, human and material resources, as well as patient potential.
At RCTs, we go one step further by leveraging our team of experienced Clinical Research Associates (CRAs), over 35 years of field expertise, and in-depth knowledge of investigator sites and patient pathways. Our approach combines operational experience with a data‑driven methodology.
Our previous experience with the shortlisted sites
Our relationships with key opinion leaders and scientific societies
Medico-administrative databases to objectively assess the active patient pool
Public clinical trial databases
We can also benchmark our analyses against solutions developed by companies specialized in patient screening.
Finally, we can activate our partnerships with LyREC, a clinical investigation center, or with networks of independent nurses for decentralized trials.
Selecting the right sites strengthens site engagement, accelerates patient recruitment, and improves data quality.